Literature DB >> 26338831

Left Ventricular Lead Electrical Delay Is a Predictor of Mortality in Patients With Cardiac Resynchronization Therapy.

Tomas Roubicek1, Dan Wichterle2, Pavel Kucera2, Pavel Nedbal2, Jindrich Kupec2, Jana Sedlakova2, Jan Cerny2, Jan Stros2, Josef Kautzner2, Rostislav Polasek2.   

Abstract

BACKGROUND: Electric left ventricular lead position, assessed by the electric delay from the beginning of the QRS complex to the local LV electrogram (QLV), was found in previous studies to be a strong predictor of short-term response to cardiac resynchronization therapy. We hypothesized that suboptimum electric position of the left ventricular lead is associated with an excess of heart failure events and mortality. METHODS AND
RESULTS: We analyzed the clinical outcome of patients with left bundle branch block or intraventricular conduction delay treated with cardiac resynchronization therapy at our institution during 9 years. Baseline clinical characteristics, QLV/QRS duration (QLV ratio) at cardiac resynchronization therapy implant, and data about heart failure hospitalization and mode of death were collected in 329 patients who were followed for a period of 3.3±1.9 years. Of them, 83 were hospitalized for heart failure and 83 died. Event rates for all-cause mortality, cardiac mortality, noncardiac mortality, heart failure mortality, and sudden death were 25.2%, 14.9%, 10.3%, 12.2%, and 2.1%, respectively. Patients with a QLV ratio ≤0.70 had significantly worse event-free survival for all study end points--hazard ratio, 1.6; 95% confidence interval, 1.0 to 2.4; P=0.05 for heart failure hospitalization; hazard ratio, 2.9; 95% confidence interval, 1.6 to 5.5; P=0.001 for heart failure mortality; hazard ratio, 1.8; 95% confidence interval, 1.1 to 2.7; P=0.01 for cardiac mortality; and hazard ratio, 2.1; 95% confidence interval, 1.2 to 3.7; P=0.01 for all-cause mortality. In multivariable analysis, QLV ratio ≤0.70 remained associated with all study end points.
CONCLUSIONS: Electric left ventricular lead position in cardiac resynchronization therapy patients was a significant predictor of heart failure hospitalization and mortality.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  bundle-branch block; cardiac resynchronization therapy; heart failure; hospitalization; mortality

Mesh:

Year:  2015        PMID: 26338831     DOI: 10.1161/CIRCEP.115.003004

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  10 in total

1.  Coronary sinus lead delay index for optimization of coronary sinus lead placement.

Authors:  Mevlüt Koç; Onur Kaypakli; Gökhan Gözübüyük; Durmus Yıldıray Şahin
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-30       Impact factor: 1.468

2.  Characterizing left ventricular mechanical and electrical activation in patients with normal and impaired systolic function using a non-fluoroscopic cardiovascular navigation system.

Authors:  Christopher Piorkowski; Arash Arya; Craig D Markovitz; Hedi Razavi; Chunlan Jiang; Stuart Rosenberg; Ole-A Breithardt; Sascha Rolf; Silke John; Jedrzej Kosiuk; Yan Huo; Michael Döring; Sergio Richter; Kyungmoo Ryu; Thomas Gaspar; Frits W Prinzen; Gerhard Hindricks; Philipp Sommer
Journal:  J Interv Card Electrophysiol       Date:  2018-01-31       Impact factor: 1.900

3.  Changes in the optimal cardiac resynchronization therapy pacing configuration during physiologic stress.

Authors:  Brett D Atwater; W Schuyler Jones; Zak Loring; Daniel J Friedman
Journal:  J Electrocardiol       Date:  2020-08-19       Impact factor: 1.438

Review 4.  Toward Sex-Specific Guidelines for Cardiac Resynchronization Therapy?

Authors:  Robbert Zusterzeel; Kimberly A Selzman; William E Sanders; Kathryn M O'Callaghan; Daniel A Caños; Kevin Vernooy; Frits W Prinzen; Anton P M Gorgels; David G Strauss
Journal:  J Cardiovasc Transl Res       Date:  2015-12-10       Impact factor: 4.132

5.  Maximization of interventricular conduction time by means of quadripolar leads for cardiac resynchronization therapy.

Authors:  Giuseppe Stabile; Valter Bianchi; Francesco Solimene; Assunta Iuliano; Quintino Parisi; Patrizia Pepi; Mario Bocchiardo; Francesco Urraro; Antonio De Simone; Roberto Ospizio; Antonio D'Onofrio
Journal:  J Interv Card Electrophysiol       Date:  2017-08-10       Impact factor: 1.900

6.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

7.  Programming Cardiac Resynchronization Therapy for Electrical Synchrony: Reaching Beyond Left Bundle Branch Block and Left Ventricular Activation Delay.

Authors:  Niraj Varma; David O'Donnell; Mohammed Bassiouny; Philippe Ritter; Carlo Pappone; Jan Mangual; Daniel Cantillon; Nima Badie; Bernard Thibault; Brian Wisnoskey
Journal:  J Am Heart Assoc       Date:  2018-02-06       Impact factor: 5.501

8.  Inadvertent QRS prolongation by an optimization device-based algorithm in patients with cardiac resynchronization therapy.

Authors:  Kamil Sedláček; Rostislav Polášek; Helena Jansová; Domenico Grieco; Pavel Kučera; Josef Kautzner; Darrel P Francis; Dan Wichterle
Journal:  PLoS One       Date:  2022-09-26       Impact factor: 3.752

9.  Lateral left ventricular lead position is superior to posterior position in long-term outcome of patients who underwent cardiac resynchronization therapy.

Authors:  Anett Behon; Walter Richard Schwertner; Eperke Dóra Merkel; Attila Kovács; Bálint Károly Lakatos; Endre Zima; László Gellér; Valentina Kutyifa; Annamária Kosztin; Béla Merkely
Journal:  ESC Heart Fail       Date:  2020-10-22

10.  Novel active fixation lead guided by electrical delay can improve response to cardiac resynchronization therapy in heart failure.

Authors:  Matteo Casale; Maurizio Mezzetti; Marianna Gigliotti De Fazio; Loredana Caccamo; Paolo Busacca; Giuseppe Dattilo
Journal:  ESC Heart Fail       Date:  2021-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.